Form D · Pharmaceuticals

DisperSol Technologies, LLC

Georgetown, TX · CIK 0001541408

Offering snapshot reported Oct 16, 2020 · SEC filing

Reported sold
$4.69M
Offering amount: $5M
Investors reported
3
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Oct 5, 2020
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Oct 16, 2020Initial$4,690,836No comparison3SEC filing
Jan 22, 2018Initial$16,028,748No comparison4SEC filing
Feb 2, 2016Initial$12,000,000No comparison3SEC filing
Mar 10, 2014Initial$3,021,690No comparison12SEC filing
May 29, 2013Amendment$611,834$0vs May 29, 201311SEC filing
May 29, 2013Initial$611,834No comparison11SEC filing
Feb 6, 2012Amendment$641,693$0vs Feb 3, 201211SEC filing
Feb 3, 2012Initial$641,693No comparison11SEC filing

Offering details

Securities
Equity
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-378147

Source: Form D, filed Oct 16, 2020. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Chris Brough Director
Edward Hobart Director, Executive
Shaun Kirkpatrick Director
James Mack Director
Edward M. Rudnic, Ph.D. Director, Executive
Jeffrey D. Samberg Director
Dustin Smith Executive
Gershon Yaniv Director

Issuer details

Industry: Pharmaceuticals (See others in industry)

Address:
111 W. Cooperative Way Bldg. 3, Ste. 300
Georgetown, TX, 78626